Patents by Inventor Punit P. Seth

Punit P. Seth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugated antisense compounds and their use
    Patent number: 9181549
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: November 10, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
    Publication number: 20150315594
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Application
    Filed: May 1, 2015
    Publication date: November 5, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Compositions and methods for modulating apolipoprotein C-III expression
    Patent number: 9163239
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 20, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • Modified 5? diphosphate nucleosides and oligomeric compounds prepared therefrom
    Patent number: 9156873
    Abstract: Provided herein are modified 5? diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5? diphosphate nucleosides are provided that can be further modified at the 2? and 5? positions. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The oligomeric compounds are also expected to be useful as primers and probes in diagnostic applications.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: October 13, 2015
    Assignees: Isis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Muthiah Manoharan, Eric E. Swayze, Kallanthottathil G. Rajeev, Ivan Zlatev
  • SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20150275208
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
  • Compositions and methods for modulating HBV expression
    Patent number: 9145558
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 29, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOSIDES AND USES THEREOF
    Publication number: 20150267195
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer sugar motif. In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 24, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Punit P. Seth, Susan M. Freier, Brett P. Monia, Eric E. Swayze
  • OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE
    Publication number: 20150259681
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: February 20, 2015
    Publication date: September 17, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • 5? modified nucleosides and oligomeric compounds prepared therefrom
    Patent number: 9127033
    Abstract: The present invention provides 5? modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5?-substituent and an optional 2? substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Conjugated antisense compounds and their use
    Patent number: 9127276
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • BICYCLIC CYCLOHEXOSE NUCLEIC ACID ANALOGS
    Publication number: 20150191727
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
    Publication number: 20150176007
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 25, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20150159163
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Short antisense compounds with gapmer configuration
    Patent number: 9045754
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: June 2, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
    Publication number: 20150126720
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: December 31, 2014
    Publication date: May 7, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
    Publication number: 20150126718
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20150126719
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • TRICYCLIC NUCLEIC ACID ANALOGS
    Publication number: 20150112055
    Abstract: The present disclosure provides tricyclic nucleosides and oligomeric compounds prepared therefrom. The tricyclic nucleosides each have a tricyclic ribosyl sugar moiety wherein a bridge between the 2? and 4? ribosyl ring carbon atoms further comprises a fused carbocyclic or heterocyclic ring. The tricyclic nucleosides are expected to be useful for enhancing properties of oligomeric compounds including for example binding affinity and nuclease resistance.
    Type: Application
    Filed: March 20, 2013
    Publication date: April 23, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze, Stephen Hanessian, Benjamin R. Schroeder, Robert D. Giacometti, Bradley L. Merner
  • Bicyclic cyclohexose nucleic acid analogs
    Patent number: 9012421
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: April 21, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • Tetrahydropyran nucleic acid analogs
    Patent number: 9005906
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: April 14, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth